骨髓和脐血细胞的骨内注射：一种与更高播散效率相关的移植替代方法。

Intra-bone marrow injection of bone marrow and cord blood cells: an alternative way of transplantation associated with a higher seeding efficiency.

作者信息

Castello Sandra, Podestà Marina, Menditto Vincenzo G, Ibatici Adalberto, Pitto Anna, Figari Osvaldo, Scarpati Daniele, Magrassi Lorenzo, Bacigalupo Andrea, Piaggio Giovanna, Frassoni Francesco

机构信息

Centro Cellule Staminali e Terapia Cellularee, Università di Pavia, Italy.

出版信息

Exp Hematol. 2004 Aug;32(8):782-7. doi: 10.1016/j.exphem.2004.05.026.

DOI:10.1016/j.exphem.2004.05.026

PMID:15308330

Abstract

OBJECTIVE

Intravenous (IV) injection is currently the normal method for transplanting hematopoietic cells. However, the problem of seeding efficiency and homing is relevant especially when a limited number of stem cells is available. Intra-bone marrow (IBM) injection of bone marrow cells (BMCs) may overcome this problem.

MATERIALS AND METHODS

Irradiated (750 cGy) C57BL/6J mice were transplanted with 1 x 10(5) BMCs harvested from transgenic mice expressing an enhanced version of the green fluorescent protein (EGFP+) via IBM or with 1 x 10(6) EGFP+ BMCs via IV. Irradiated (320 cGy) NOD/SCID mice were transplanted with 1 x 10(6) human cord blood (CB) cells via IBM or with 1 x 10(7) human CB cells via IV.

RESULTS

In C57BL/6J mice after 90 days, the fraction of EGFP+ cells harvested was 37% and 53% in IV-treated and IBM-treated (contralateral tibia and femur in the IBM) mice, respectively: the expansion folds were 114 and 1760, respectively. In NOD/SCID mice, the percentages of CD45+ cells and CD45+/CD34+ cells were, at 30 days, 3.3% and 0.3% in IV-treated mice, and 4.4% and 1.1% in IBM-treated mice. At 60 days, the percentages of CD45+ cells and CD45+/CD34+ cells were 2.1% and 0.3% in IV-treated mice and 1.4% and 0.4% in IBM-treated mice. At day 90 the percentages of CD45+ cells and CD45+/CD34+ cells were 3% and 0.3% in IV-treated mice and 2.3% and 0.4% in IBM-treated mice.

CONCLUSION

Our data demonstrate that IBM transplantation is associated with a seeding efficiency 15 times greater than IV transplantation. IBM transplantation may improve the results of transplant and may be useful in several settings: 1) when a limited number of hematopoietic progenitors are available; and 2) in experiments aiming to place in the bone marrow stem cells of other lineages (CNS, muscle, etc.).

摘要

目的

静脉注射目前是移植造血细胞的常规方法。然而，尤其是当可用的干细胞数量有限时，植入效率和归巢问题就显得很重要。骨髓内（IBM）注射骨髓细胞（BMC）可能会克服这个问题。

材料与方法

将经辐照（750 cGy）的C57BL/6J小鼠通过IBM移植1×10⁵个从表达增强型绿色荧光蛋白（EGFP⁺）的转基因小鼠收获的BMC，或通过静脉注射移植1×10⁶个EGFP⁺ BMC。将经辐照（320 cGy）的NOD/SCID小鼠通过IBM移植1×10⁶个人类脐带血（CB）细胞，或通过静脉注射移植1×10⁷个人类CB细胞。

结果

在C57BL/6J小鼠中，90天后，静脉注射处理组和IBM处理组（IBM处理组为对侧胫骨和股骨）收获的EGFP⁺细胞比例分别为37%和53%；扩增倍数分别为114和1760。在NOD/SCID小鼠中，静脉注射处理组在30天时CD45⁺细胞和CD45⁺/CD34⁺细胞的百分比分别为3.3%和0.3%，IBM处理组为4.4%和1.1%。在60天时，静脉注射处理组CD45⁺细胞和CD45⁺/CD34⁺细胞的百分比分别为2.1%和0.3%，IBM处理组为1.4%和0.4%。在90天时，静脉注射处理组CD45⁺细胞和CD45⁺/CD34⁺细胞的百分比分别为3%和0.3%，IBM处理组为2.3%和0.4%。